Established in 2020 Wednesday, April 17, 2024


Cellular nanosponges could soak up SARS-CoV-2
In this illustration, a nanosponge coated with a human cell membrane acts as a decoy to prevent a virus from entering cells. Image: Adapted from Nano Letters 2020.



WASHINGTON, DC.- Scientists are working overtime to find an effective treatment for COVID-19, the illness caused by the new coronavirus, SARS-CoV-2. Many of these efforts target a specific part of the virus, such as the spike protein. Now, researchers reporting in Nano Letters have taken a different approach, using nanosponges coated with human cell membranes –– the natural targets of the virus –– to soak up SARS-CoV-2 and keep it from infecting cells in a petri dish.




To gain entry, SARS-CoV-2 uses its spike protein to bind to two known proteins on human cells, called ACE2 and CD147. Blocking these interactions would keep the virus from infecting cells, so many researchers are trying to identify drugs directed against the spike protein. Anthony Griffiths, Liangfang Zhang and colleagues had a different idea: making a nanoparticle decoy with the virus’ natural targets, including ACE2 and CD147, to lure SARS-CoV-2 away from cells. And to test this idea, they conducted experiments with the actual SARS-CoV-2 virus in a biosafety level 4 lab.

The researchers coated a nanoparticle polymer core with cell membranes from either human lung epithelial cells or macrophages –– two cell types infected by SARS-CoV-2. They showed that the nanosponges had ACE2 and CD147, as well as other cell membrane proteins, projecting outward from the polymer core. When administered to mice, the nanosponges did not show any short-term toxicity. Then, the researchers treated cells in a dish with SARS-CoV-2 and the lung epithelial or macrophage nanosponges. Both decoys neutralized SARS-CoV-2 and prevented it from infecting cells to a similar extent. The researchers plan to next test the nanosponges in animals before moving to human clinical trials. In theory, the nanosponge approach would work even if SARS-CoV-2 mutates to resist other therapies, and it could be used against other viruses, as well, the researchers say.

The authors acknowledge funding from the Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense.







Today's News

June 25, 2020

Researchers use stem cells to model the immune response to COVID-19

Finding the guts to fight off COVID-19

Black hole swallows much smaller mysterious object

Yale named Top Ten Center of Biomedical Research by The Hartwell Foundation

Tulane scientists to share in $20 million NSF award for materials research

NASA's TESS, Spitzer missions discover a world orbiting a unique young star near us

Lillian Anderson honored with Helen Grenga Outstanding Woman Engineer Award

Gear treated with 'forever chemicals' poses risk to firefighters

Critically ill patients with COVID-19 at risk to develop heart rhythm disorders

Medtronic awards $1M gift toward establishing new endowed professorship at Case Western Reserve University Med School

Is teleportation possible? Yes, in the quantum world

Tulane University researchers develop synthetic antibody against COVID-19

New "soft power": batteries safe and stable as skin cream

As labs reopen, Rochester researchers adapt to COVID-19 precautions in innovative ways

Study yields clues to how drug may boost aged mitochondria

Wildfire smoke has immediate harmful health effects: UBC study

New gold nanoparticle purifies water of difficult pollutants

Cellular nanosponges could soak up SARS-CoV-2



 


Editor & Publisher: Jose Villarreal
Art Director: Juan José Sepúlveda Ramírez



Tell a Friend
Dear User, please complete the form below in order to recommend the ResearchNews newsletter to someone you know.
Please complete all fields marked *.
Sending Mail
Sending Successful